Biostem Technologies Inc (BSEM)

$3.33 -0.02 (-0.72%)
Market Cap 56.20M
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio 4.68
Forward PE 15.29
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 63,200
Avg Vol 70,074
Day's Range N/A - N/A
Shares Out 16.78M
Stochastic %K 14%
Beta -0.44
Analysts Strong Buy
Price Target $25.50

Company Profile

BioStem Technologies, Inc., a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases. The company is also engages in the repackaging and distribution of active pharmaceutical ingredients and other pharmaceutical compounding s...

Industry: Biotechnology
Sector: Healthcare
Phone: 954 380 8342
Address:
2836 Center Port Circle, Pompano Beach, United States
GlobalInsights
GlobalInsights Nov. 19 at 5:25 PM
$BSEM Part 5 What I find bizarre is the statement in the CC saying, “We have long been an advocate for reform of the Medicare reimbursement system for skin substitutes”. Has anyone else heard them say that until now? With a Q4 2024 GM of 95.4%, which is unheard of and very few companies ever attain that, it might be the result of extremely high selling prices, $2K+ that triggered the CMS investigations. Around mid Nov 2024 the company announced their Q3 2024 financials, and the stock subsequently traded at a high of $28.26 based on the release of financials that might have been improperly reported. I would think those that bought at that time or any time during 2024 to mid 2025 might have a case for being misled. Also, will the final restatements cause any executive compensation based on the inflated numbers lead to claw backs of bonuses if those bonuses were based on revenue, which I don’t know.
0 · Reply
GlobalInsights
GlobalInsights Nov. 19 at 5:23 PM
$BSEM Part 4 Engaging a new audit firm KPMG is a good thing, but when I went through this exact scenario the new auditor started the audit from scratch and did not rely on the prior auditors opinions. My experience was the new auditor went through the entire process to determine if the new systems in place were proper & then test it over 2 quarters to make sure it was operating without weaknesses. Then our auditor Deloitte had their audit audited by another firm to ensure they didn’t make any mistakes. Whether the 2 Q test phase & audit the auditor occur here is unknown and may not occur. If it does things will most likely will take longer.
0 · Reply
GlobalInsights
GlobalInsights Nov. 19 at 5:21 PM
$BSEM Part 3 They highlight how the new accounting treatment lowered many of the financial metrics, which makes sense & continued to paint a very positive picture. What they didn’t do is provide investors with what the expected financial impact will be once the $127 reimbursement is in place. The high margins they have reported in the past were so high, unheard of, my opinion is that it might be the result of selling products at the $2000+ level all of which might drastically reduce their 2026 financial metrics. So, since the current reimbursement is still in place I would expect Q4 to be a last push on sales at the high prices & then Q1 of 2026 will be a completely different story that will give shareholders better clarity on how financially sound the overall business is.
1 · Reply
GlobalInsights
GlobalInsights Nov. 19 at 5:20 PM
$BSEM Part 2 They stated they had 40% product volume growth Q over Q. I find that interesting, reminds me of all the EV sales that happened in the US just prior to the $7500 incentive going away. They did not explain what drove that volume increase other than saying they have great products. I expect it may have more to do with a highly incentivized sales force trying to sell as much product as possible before yr end, most likely sales force incentives will drop significantly next yr. They said they restated their financials & showed that for Q3, but as far as I could tell they did not show the restated 9-month financials for 2025 which all companies do & they offered no explanation. Investors need to see the YTD restatement, not just 1 quarter.
0 · Reply
GlobalInsights
GlobalInsights Nov. 19 at 5:18 PM
$BSEM Part 1 I finally had an opportunity to review BSEM’s earning release & CC transcript. 1st it seems the new CFO has brought more transparency when reporting on the company & most likely helping to influence that behavior in the other executives. Also, finally getting clarity on the FDA warning letter resolution & closing that out was a good thing. In the past the company claimed the FDA warning letter was only for products they no longer produce. But as I said in the past a warning letter deals with the a company’s quality system compliance & affects all areas of the business.
0 · Reply
Biotech_rabbi
Biotech_rabbi Nov. 14 at 11:55 AM
$BSEM Q3 Transcript https://seekingalpha.com/article/4843588-biostem-technologies-inc-bsem-q3-2025-earnings-call-transcript
1 · Reply
IRISHMIKE1
IRISHMIKE1 Nov. 13 at 11:22 PM
$BSEM wow, we need some news on uplifting to finally get this dog to wag its tail!!
0 · Reply
jimmythefish
jimmythefish Nov. 13 at 9:12 PM
$BSEM https://ir.biostemtechnologies.com/single-news-releases/?webmasterId=104915&storyId=8576516562851842
3 · Reply
jimmythefish
jimmythefish Nov. 13 at 9:07 PM
$BSEM from Q report Remediated all concerns noted from FDA’s prior 2023 inspection and the associated Form 483. The FDA conducted a new 361 inspection this quarter, which was completed with no nonconformances, comments or observations
2 · Reply
jimmythefish
jimmythefish Nov. 13 at 5:58 PM
$BSEM results after hrs today, will be interesting to see how company reports its earnings. I presume it will change as per any guidelines they received from SEC. Expecting decrease in revenue from last year, but increase from last Q. Hopefully will see increase in cash on hand.
0 · Reply
Latest News on BSEM
No data available.
GlobalInsights
GlobalInsights Nov. 19 at 5:25 PM
$BSEM Part 5 What I find bizarre is the statement in the CC saying, “We have long been an advocate for reform of the Medicare reimbursement system for skin substitutes”. Has anyone else heard them say that until now? With a Q4 2024 GM of 95.4%, which is unheard of and very few companies ever attain that, it might be the result of extremely high selling prices, $2K+ that triggered the CMS investigations. Around mid Nov 2024 the company announced their Q3 2024 financials, and the stock subsequently traded at a high of $28.26 based on the release of financials that might have been improperly reported. I would think those that bought at that time or any time during 2024 to mid 2025 might have a case for being misled. Also, will the final restatements cause any executive compensation based on the inflated numbers lead to claw backs of bonuses if those bonuses were based on revenue, which I don’t know.
0 · Reply
GlobalInsights
GlobalInsights Nov. 19 at 5:23 PM
$BSEM Part 4 Engaging a new audit firm KPMG is a good thing, but when I went through this exact scenario the new auditor started the audit from scratch and did not rely on the prior auditors opinions. My experience was the new auditor went through the entire process to determine if the new systems in place were proper & then test it over 2 quarters to make sure it was operating without weaknesses. Then our auditor Deloitte had their audit audited by another firm to ensure they didn’t make any mistakes. Whether the 2 Q test phase & audit the auditor occur here is unknown and may not occur. If it does things will most likely will take longer.
0 · Reply
GlobalInsights
GlobalInsights Nov. 19 at 5:21 PM
$BSEM Part 3 They highlight how the new accounting treatment lowered many of the financial metrics, which makes sense & continued to paint a very positive picture. What they didn’t do is provide investors with what the expected financial impact will be once the $127 reimbursement is in place. The high margins they have reported in the past were so high, unheard of, my opinion is that it might be the result of selling products at the $2000+ level all of which might drastically reduce their 2026 financial metrics. So, since the current reimbursement is still in place I would expect Q4 to be a last push on sales at the high prices & then Q1 of 2026 will be a completely different story that will give shareholders better clarity on how financially sound the overall business is.
1 · Reply
GlobalInsights
GlobalInsights Nov. 19 at 5:20 PM
$BSEM Part 2 They stated they had 40% product volume growth Q over Q. I find that interesting, reminds me of all the EV sales that happened in the US just prior to the $7500 incentive going away. They did not explain what drove that volume increase other than saying they have great products. I expect it may have more to do with a highly incentivized sales force trying to sell as much product as possible before yr end, most likely sales force incentives will drop significantly next yr. They said they restated their financials & showed that for Q3, but as far as I could tell they did not show the restated 9-month financials for 2025 which all companies do & they offered no explanation. Investors need to see the YTD restatement, not just 1 quarter.
0 · Reply
GlobalInsights
GlobalInsights Nov. 19 at 5:18 PM
$BSEM Part 1 I finally had an opportunity to review BSEM’s earning release & CC transcript. 1st it seems the new CFO has brought more transparency when reporting on the company & most likely helping to influence that behavior in the other executives. Also, finally getting clarity on the FDA warning letter resolution & closing that out was a good thing. In the past the company claimed the FDA warning letter was only for products they no longer produce. But as I said in the past a warning letter deals with the a company’s quality system compliance & affects all areas of the business.
0 · Reply
Biotech_rabbi
Biotech_rabbi Nov. 14 at 11:55 AM
$BSEM Q3 Transcript https://seekingalpha.com/article/4843588-biostem-technologies-inc-bsem-q3-2025-earnings-call-transcript
1 · Reply
IRISHMIKE1
IRISHMIKE1 Nov. 13 at 11:22 PM
$BSEM wow, we need some news on uplifting to finally get this dog to wag its tail!!
0 · Reply
jimmythefish
jimmythefish Nov. 13 at 9:12 PM
$BSEM https://ir.biostemtechnologies.com/single-news-releases/?webmasterId=104915&storyId=8576516562851842
3 · Reply
jimmythefish
jimmythefish Nov. 13 at 9:07 PM
$BSEM from Q report Remediated all concerns noted from FDA’s prior 2023 inspection and the associated Form 483. The FDA conducted a new 361 inspection this quarter, which was completed with no nonconformances, comments or observations
2 · Reply
jimmythefish
jimmythefish Nov. 13 at 5:58 PM
$BSEM results after hrs today, will be interesting to see how company reports its earnings. I presume it will change as per any guidelines they received from SEC. Expecting decrease in revenue from last year, but increase from last Q. Hopefully will see increase in cash on hand.
0 · Reply
Biotech_rabbi
Biotech_rabbi Nov. 6 at 11:51 AM
$BSEM POMPANO BEACH, Fla., Nov. 05, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company specializing in placental-derived biologics for advanced wound care, today commented on the Centers for Medicare & Medicaid Services’ (“CMS”) Calendar Year 2026 Physician Fee Schedule (PFS) final rule, which reforms Medicare reimbursement for skin substitutes. https://www.globenewswire.com/news-release/2025/11/05/3181920/0/en/BioStem-Technologies-Provides-Comments-on-CMS-CY-2026-Final-Medicare-Reimbursement-Rule-Changes-for-Skin-Substitutes.html
0 · Reply
jimmythefish
jimmythefish Nov. 5 at 1:48 PM
$BSEM BioStem Technologies Secures Land Purchase POMPANO BEACH, Fla., Nov. 05, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announced the purchase of land for its future headquarters in the Research Park at Florida Atlantic University® in Boca Raton. Under the terms of an agreement with the City, the Company will receive up to $300,000 in economic incentives for the creation of up to 100 jobs over a five-year period. The four-acre land parcel that the Company purchased will be the future home of all administrative offices, manufacturing, and distribution. BioStem has not yet set a timetable for its relocation to the new site. “As we contemplate the long-term vision for BioStem, we anticipate the need to expand our operations in support of the growing demand for our advanced wound care products.
1 · Reply
GlobalInsights
GlobalInsights Nov. 4 at 5:03 PM
$BSEM There we go. New low of $4 does it now go into the $3’s?
0 · Reply
GlobalInsights
GlobalInsights Nov. 4 at 3:10 PM
$BSEM Seems the stock is on the way to test the 52w low. If it fails to hold there is a possibility stock heads into the $3’s
1 · Reply
GlobalInsights
GlobalInsights Nov. 3 at 3:06 PM
$BSEM I would expect after CMS ruling the companies rev will most likely decline up to 90% next yr. Also if the new auditor requires a restatement of prior quarter/years financials the companies solvency may come into question.
0 · Reply
GlobalInsights
GlobalInsights Nov. 1 at 3:17 AM
$BSEM CMS final rule $127 sq/cm https://www.cms.gov/newsroom/fact-sheets/calendar-year-cy-2026-medicare-physician-fee-schedule-final-rule-cms-1832-f
0 · Reply
Biotech_rabbi
Biotech_rabbi Oct. 31 at 1:06 PM
$BSEM https://www.globenewswire.com/news-release/2025/10/31/3178220/0/en/BioStem-Technologies-Reports-Positive-Top-Line-Clinical-Results-Demonstrating-Superior-Outcomes-with-BioRetain-Allograft-in-Diabetic-Foot-Ulcers.html
2 · Reply
IRISHMIKE1
IRISHMIKE1 Oct. 29 at 5:10 PM
$BSEM $5 here we come !
1 · Reply
GlobalInsights
GlobalInsights Oct. 29 at 12:35 PM
$BSEM If you recall many months ago I said based on their material weaknesses they would most likely need to change to a better auditor because the current auditor failed the company.
0 · Reply
jimmythefish
jimmythefish Oct. 28 at 5:13 AM
$BSEM https://ir.biostemtechnologies.com/single-news-releases/?webmasterId=104915&storyId=6980966907879104
0 · Reply
GlobalInsights
GlobalInsights Oct. 16 at 4:37 PM
$BSEM https://carolinefifemd.com/2025/10/16/skin-substitute-fraud-arizona/ 1
0 · Reply
marben
marben Oct. 14 at 8:26 PM
$BSEM WOOOT!! Only down 6% in the past month baby!
1 · Reply